Clinical trial NCT00496067: Uterine Artery Occlusion for Fibroid Related Bleeding
Official title: An Evaluation of a Doppler-Guided Uterine Artery Occlusion Device as Treatment for the Reduction of Fibroid-Associated Bleeding
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Menorrhagia
Uterine Fibroids
Keywords: Fibroids
Menorrhagia
Menorrhagia associated with uterine fibroids
Lead sponsor: Ethicon, Inc.
Sponsor class: INDUSTRY
First posted: 2007-07-04
Enrollment: 91
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the safety and effectiveness of Doppler guided Uterine Artery Occlusion (D-UAO) as treatment for the reduction of fibroid-associated symptoms.

Detailed description: DUAO is intended for bilateral occlusion of the uterine arteries

Eligibility criteria: Inclusion Criteria:

* 25 to 50 years of age
* Subject has a negative urine or blood pregnancy test prior to the procedure. At the time of enrollment to the study, the subject has no intent of further childbearing and intends to use appropriate contraception throughout the first 12 months of the study period (unless sterilized)
* Normal pap smear within 36 months of study procedure (most recent)
* Cervix suitable for tenaculum placement as determined by pelvic exam (adequate length of cervix, absence of cervical fibroid/lower fibroid to prevent clamp placement)
* At least one intra-mural or sub-serosal or sub-mucosal uterine fibroid with a minimum diameter of greater than or equal to 3 cm, and all fibroids with a diameter less than or equal to 8cm with a prevailing pathology (e.g., as opposed to adenomyosis) of fibroids determined through ultrasound
* Symptomatic subject presenting with at least one of the following fibroid symptoms: pelvic pressure, menorrhagia, metrorrhagia, pelvic pain, increasing abdominal girth or dyspareunia due to fibroids.
* Subject has evidence of bilateral ureteric flow
* Subject agrees to participate in the study, including completion of all study-related procedures and evaluations, and documents this agreement by signing the Ethics Committee-approved informed consent.

Exclusion Criteria:

* Pregnancy as confirmed by positive urine or blood pregnancy test
* Menopausal as defined by elevated follicle-stimulating hormone (FSH) and decreased oestradiol hormone levels as determined by the hospital local laboratory reference range criteria
* Presence of any pedunculated sub-mucosal or pedunculated sub-serosal fibroid(s) as determined by MRI, ultrasound or hysteroscopy
* Presence of an intra-uterine device (IUD)
* Any hydronephrosis as determined on renal ultrasound prior to the procedure
* Clinical history of any thrombo-embolic disease or known thrombophilia
* Blood Urine Nitrogen (BUN) greater than 7.2mmol/L\* and/or serum creatinine greater than 106μmol/L\* unresolved with change in diet or hydration
* History or current evidence of gynecologic malignancy (confirmed by hysteroscopy or endometrial biopsy), atypical endometrial hyperplasia, or chronic pelvic inflammatory disease
* Pelvic mass outside the uterus other than uterine fibroids
* Any current acute or chronic systemic infection or localized pelvic infection, including a urinary tract infection
* Use of Gonadotropin-Releasing Hormone (GnRH) agonist, danozol or mifepristone within 6-months prior to the start of the study procedure
* Using anticoagulation therapy (except over the counter treatments (e.g. aspirin)), or have an underlying bleeding disorder
* Unsuitable for MRI examination (e.g. severe claustrophobia, non-MRI-compatible implanted metalloid devices)
* Prior endometrial ablation, uterine artery embolization, or uterine artery ligation
* Poor procedural candidate due to medical conditions as determined by the investigator (e.g. anesthesia class, renal insufficiency, heart disease);

Primary outcomes:
measure: Lack of surgical re-intervention
timeFrame: Post-op through end of study
Secondary outcomes:
measure: Percentage of subjects with improvement in Uterine Fibroid Symptom Quality of Life (UFS-QOL) Symptom Severity and Health Related Quality of Life (HRQL) scores.
timeFrame: 6, 12 and 24 months
measure: Mean improvement in UFS-QOL Symptom Severity and HRQL transformed scores.
timeFrame: 6, 12 and 24 months
measure: Mean HRQL subscales.
timeFrame: 6, 12 and 24 months
measure: Percentage of subjects with reduction of 50% or greater in Pictorial Blood Loss Assessment Chart (PBLAC) score.
timeFrame: 6 and 12 months
measure: Mean change in PBLAC scores.
timeFrame: Baseline to 6 and 12 months
measure: Percentage of subjects with decrease in fibroid load based on independent MRI review.
timeFrame: 6 months
measure: Percentage of subjects with maintenance of menses as defined by continuation of menstrual cycles without an interruption of three consecutive months
timeFrame: 12 months
measure: Percentage of subjects with procedural satisfaction as defined by responses of either satisfied or very satisfied.
timeFrame: 12 months
measure: Lack of surgical re-intervention.
timeFrame: 24 months
measure: Pain score
timeFrame: Discharge or 24-hour post clamp removal, whichever is earlier
measure: Days to normal activities (household, work and sexual intercourse)
timeFrame: Post procedure
measure: Euro-QOL expressed as change from baseline for each of the 6 domains and Visual Analogue Scale (VAS)
timeFrame: 1, 3, 6 and 12 months
measure: Nights in hospital
timeFrame: Total and post procedure
Other outcomes:
Locations:
city: Viborg
country: Denmark
facility: Viborg County Hospital
city: Angers cedex
country: France
facility: University Hospital
city: Clamart Cedex
country: France
facility: Service de Gynecologie Obsterique, Hopital Antoine Beclere
city: Dunkerque
country: France
facility: Maternite les Bazennes
city: Lille Cedex
country: France
facility: CHRU de Lille, Hopital Jeanne de Flandre
city: Erlangen
country: Germany
facility: Universitaeklinikum Erlangen
city: Tubingen
country: Germany
facility: Universitats-Frauenklinik Tubingen
city: Amsterdam
country: Netherlands
facility: VU Medical Center
city: Oslo
country: Norway
facility: Ullevaal University
city: Bern
country: Switzerland
facility: Universitats-Frauenklinik
city: Bradford
country: United Kingdom
facility: M1 Maternity, Bradford Royal Infirmary
city: Hull
country: United Kingdom
facility: Hull and East Yorkshire Women & Children Hospital
city: London
country: United Kingdom
facility: Elizabeth Garret Anderson Hospital
city: Margate
country: United Kingdom
facility: Queen Elizabeth the Queen Mother Hospital
Study officials:
affiliation: Ethicon, Inc.
name: David Robinson, MD
role: STUDY_DIRECTOR
References: